Funding for this research was provided by:
H Lundbeck A/S (-)
Received: 9 July 2019
Accepted: 4 March 2020
First Online: 14 March 2020
Ethics approval and consent to participate
: Physicians in the study participated on a voluntary basis and written consent was deemed implicit upon completion of the questionnaire. The ALTO study was approved by the Ethik-Kommission der Fakultät für Medizin der Technischen Universität München (ethics committee reference number: 5701/13).
: Not applicable.
: MXP: has received honoraria for activities as a consultant for and accepted travel or hospitality payment from Otsuka, Sunovion, Janssen, Lundbeck, Lilly, Boehringer-Ingelheim, Endo and Wyeth, as a speaker for Otsuka, Lundbeck, Janssen and Lilly, and has participated in clinical trials and studies for Janssen, Takeda, Lundbeck and Amgen and reports compensation from Lundbeck for travel and time related to this study scientific board; NB-E: Full-time employee of Lundbeck SAS at time of research; CS: Full-time employee of Lundbeck SAS at time of research; SdN: is a shareholder of Inferential, the provider of biostatistical consulting services for this publication; J-YL: Employee of Otsuka at the time of research, A-GN: Employee of Lundbeck SAS; SH: reports compensation from Lundbeck for travel and time related to this study scientific board, has received speaker honoraria from Janssen-Cilag, Eli Lilly, Sanofi-Aventis, Otsuka, Lundbeck and Johnson & Johnson, has accepted travel or hospitality payment from Janssen-Cilag, Sanofi-Aventis, Johnson & Johnson, Pfizer, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis and Eli Lilly, has participated in clinical trials sponsored or supported by Eli Lilly, Janssen-Cilag, Johnson & Johnson, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis, Servier, Pierre Fabre, Pfizer, Organon, Roche and Merck, and has received honoraria for participation in advisory-boards or activities as a consultant from Lundbeck, Otsuka, Eli Lilly, Roche, Teva, Janssen and Johnson & Johnson.